Abstracts tagged "autoimmune diseases"

Abstract Number: 0671 • ACR Convergence 2022
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca K.Leaf², Danieli Castro Oliveira de Andrade³, Megan Barber⁴, Maria G. Tektonidou⁵, Vittorio Pengo⁶, Savino Sciascia⁷, Amaia Ugarte⁸, H Michael Belmont⁹, Chary López-Pedrera¹⁰, Paul R Fortin¹¹, maria gerosa¹², Guilherme de Jesús¹³, Tatsuya Atsumi¹⁴, ZHUOLI ZHANG¹⁵, Hannah Cohen¹⁶, D. Ware Branch¹⁷, Denis WAHL¹⁸, Laura Andreoli¹⁹, Esther Rodriguez Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Yu (Ray) Zuo²³, Bahar Artim-Esen²⁴, ²⁵, Rohan Willis²⁶, Maria Laura Bertolaccini²⁷, Robert Roubey²⁸, Doruk Erkan¹ and on behalf of APS ACTION On Behalf Of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Torino, Italy, ⁸BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹²University of Milan, Milano, Italy, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁷University of Utah, Salt Lake City, UT, ¹⁸University of Lorraine, Nancy, France, ¹⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²²Hospital Clinic Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²⁶University of Texas Medical Branch, Galveston, TX, ²⁷King's College London, London, United Kingdom, ²⁸University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0758 • ACR Convergence 2022
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Azin Rouhi¹, Shahin Jamal², Marie Hudson³, Janet Pope⁴, Janet Roberts⁵, Alexandra Ladouceur³, Sara Hewitt⁶ and Carrie Ye¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Western University, London, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have shown great promise in the treatment of different malignancies. The use of ICIs has been associated with toxicities that…
Abstract Number: 0811 • ACR Convergence 2022
Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
Yael Ross¹ and Stanley Ballou², ¹Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, ²Case Western Reserve University - Metro Health, Cleveland, OH
Background/Purpose: C-reactive protein (CRP) is an acute-phase reactant widely employed clinically as a marker of inflammation. Serum CRP level is generally elevated with any type…
Abstract Number: 1066 • ACR Convergence 2022
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
Elvis Hysa, Carmen Pizzorni, Silvia Sammori, Emanuele Gotelli, Andrea Pogna, andrea cere, Carlotta Schenone, Veronica Gerli, sabrina Paolino, Alberto Sulli and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: Nailfold videocapillaroscopy (NVC) allows the safe and fast detection of different microvascular patterns in patients affected by autoimmune connective tissue diseases (CTDs). The prevalence of…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1482 • ACR Convergence 2022
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
Gayathri MS¹, Chengappa Kavadichanda², Aishwarya Gopal³, Devender Bairwa⁴, Molly Thabah¹, Sonali Sarkar⁵ and Prakash Babu Narasimhan¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Latent tuberculosis infection (L-TB) detected by mycobacterium tuberculosis (TB) IFN-γ release assay (TB-IGRA), besides identifying latent infection may predict the disease status in SLE.…
Abstract Number: 1722 • ACR Convergence 2022
The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus
Shane Bruckner¹, Braden Zeno¹, William Willis², Chad Bennett¹ and Wael Jarjour¹, ¹The Ohio State University, Columbus, OH, ²Ohio State, Reynoldsburg, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, mainly affecting young women between the ages of 15 and 45…
Abstract Number: 2017 • ACR Convergence 2022
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
Juliette Rocca¹, Maxime Beydon², Veronique Le Guern³, Eric Hachulla⁴, Jean Jacques Dubost⁵, sandrine jousse joulin⁶, Valerie Devauchelle⁷, Jacques-Eric Gottenberg⁸, Olivier Vittecoq⁹, Christian Lavigne¹⁰, Jean Schmidt¹¹, Christian Marcelli¹², Claire Larroche¹³, Xavier Mariette¹⁴, Raphaèle Seror¹⁵ and Gaetane Nocturne¹⁶, ¹APHP, Paris, France, ²Université Paris Cité, Paris, France, ³Hôpital Cochin, Paris, France, ⁴University of Lille, LILLE, France, ⁵University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁶Roche, Brest, France, ⁷Université de Bretagne Occidentale, Brest, France, ⁸University of Strasbourg, Strasbourg, France, ⁹CHU de Rouen, ROUEN, France, ¹⁰CHU Angers, Angers, France, ¹¹CHU Amiens, Amiens, France, ¹²CHU Caen, Caen, France, ¹³APHP, Bobigny, France, ¹⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁵University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ¹⁶APHP, Le Kremlin Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) patients present an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL.…
Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Andrea Largent¹, Jane Buckner², David Rawlings¹ and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…
Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Carla J. Guthridge¹, Catriona Wagner², Sohail Khan³, Michael Peercy⁴, Bobby Saunkeah⁴, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Cherokee Nation, Tahlequah, OK, ⁴Chickasaw Nation, Ada, OK
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…
Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Sophia Lutgen¹, S. Sam Lim², Laura D. Aspey², Gaobin Bao³, Charmayne Dunlop-Thomas², Jessica N. Williams² and Cristina Drenkard², ¹Mount Sinai Morningside-West, New York, NY, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
Abstract Number: 0582 • ACR Convergence 2022
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
Xiaojuan Chai¹, Yayuan Fu¹, Lifeng Liu¹, Yuxi Yan¹, Quan Zhao¹, Xiaoqing Liu², Yixin Zou¹, Jing Dai¹, Feng Tang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…
Abstract Number: 0686 • ACR Convergence 2022
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
Katsuhiko Yoneda¹, Yo Ueda¹, Kenji Tanimura², Hirotaka Yamada¹, Takaichi Okano³, Keisuke Nishimura¹, Hisashi Arase⁴, Hideto Yamada⁵ and Jun Saegusa¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Obstetrics and Gynecology, Kobe University Hospital, Kobe, Japan, ³Kobe University Hospital, Kobe, Japan, ⁴Department of Immunochemistry, Research Institute for Microbial Disease, Osaka University, Suita, Japan, ⁵Department of Obstetrics and Gynecology, Kobe University Hospital / Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. Recently, β2-glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA-DR)…
Abstract Number: 0759 • ACR Convergence 2022
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Gordon Lam¹, Andrew Laster¹, Heather Gladue¹, Ahmad Kashif¹, Erin Siceloff², Victoria Lackey¹, Cheryl Robertson¹, Ashley Toci¹, Maggie McCarter³ and Leonard Calabrese⁴, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis and Osteoporosis Consultants of the Carolinas, Stallings, NC, ³University of South Carolina, Columbia, SC, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is uncertain as these individuals were not included in clinical…
Abstract Number: 0814 • ACR Convergence 2022
Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA
Smarika Sapkota¹, Jerry Molitor², michael evans², Benjamin Kofoed³, Adam Lord³, Londyn Robinson³ and John crosson², ¹University of Colorado, Aurora, CO, ²University of Minnesota, Minneapolis, MN, ³University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The clinical significance of Dense Fine Speckled (DFS) pattern Anti-nuclear antibodies (ANA) by indirect immunofluorescence method (IIF) is unclear and has been inversely associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].